Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Interferon Gamma-1b in IPF
NCT00076635Phase 3Terminated
- Sponsor
- InterMune
- Start
- Nov 2003
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of interferon gamma-1b in idiopathic pulmonary fibrosis (IPF), sponsored by InterMune. Primary endpoints: All adverse events at 3.5 years, Survival status at 3.5 years and 1 more. Started Nov 2003; status: terminated.
02
Drugs
interferon gamma-1b
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT00076635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00076635.